118 related articles for article (PubMed ID: 38330638)
21. Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study.
Yang J; Hu M; Bai X; Ding X; Xie L; Ma J; Fan B; Yu J
Medicine (Baltimore); 2019 Sep; 98(39):e17231. PubMed ID: 31574833
[TBL] [Abstract][Full Text] [Related]
22. The Change of Soluble Programmed Death Ligand 1 (sPD-L1) in Plasma of Small Cell Lung Cancer and Its Clinical Significance.
Lu F; Dong Y; Li Q; Wang M
Comput Math Methods Med; 2022; 2022():8375349. PubMed ID: 35126639
[TBL] [Abstract][Full Text] [Related]
23. [Levels and Clinical Significances of sPD-1 and sPD-L1 in Peripheral Blood of Lymphoma Patients].
Liu XL; He P; Lei J; Zou LX; Peng L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1733-1738. PubMed ID: 38071053
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.
Kushlinskii NE; Gershtein ES; Chang VL; Korotkova EA; Alferov AA; Kontorshchikov MM; Sokolov NY; Karamysheva EI; Ognerubov NA; Stilidi IS
Klin Lab Diagn; 2021 Mar; 66(3):139-146. PubMed ID: 33793112
[TBL] [Abstract][Full Text] [Related]
25. Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
He J; Pan Y; Guo Y; Li B; Tang Y
J Immunother; 2020 Jun; 43(5):156-164. PubMed ID: 32168233
[TBL] [Abstract][Full Text] [Related]
26. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients.
Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J
Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808
[TBL] [Abstract][Full Text] [Related]
27. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
28. Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome.
Li S; Yi L; Wei X; Zhang J; Wang X; Jiang C; Yan Z; Song L; Yang B; Wei P; Gao X; Wang J; Zhang H; Zhang J
Front Cardiovasc Med; 2022; 9():971414. PubMed ID: 36119741
[TBL] [Abstract][Full Text] [Related]
29. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
[TBL] [Abstract][Full Text] [Related]
30. High Soluble Programmed Death-Ligand 1 Predicts Poor Prognosis in Patients with Nasopharyngeal Carcinoma.
Lu T; Chen Y; Li J; Guo Q; Lin W; Zheng Y; Su Y; Zong J; Lin S; Ye Y; Pan J
Onco Targets Ther; 2020; 13():1757-1765. PubMed ID: 32161471
[TBL] [Abstract][Full Text] [Related]
31. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
[TBL] [Abstract][Full Text] [Related]
32. [Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer].
Nan J; Liang L; Li L; Xiaoqin S; Xing J; Yang C
Hua Xi Kou Qiang Yi Xue Za Zhi; 2017 Jun; 35(3):286-290. PubMed ID: 28675014
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis.
Wang Y; He H
Immunotherapy; 2022 Aug; 14(12):945-956. PubMed ID: 35822688
[No Abstract] [Full Text] [Related]
34. Role of sPD-1 and sPD-Ls in the pathogenesis of connective tissue disease.
He H; He X; Zhou M; Tang Y; Dai L; Xie Z; Wang Y; Xie C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):444-454. PubMed ID: 37164928
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy.
Kim HJ; Park S; Kim KJ; Seong J
Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520
[TBL] [Abstract][Full Text] [Related]
36. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
37. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract][Full Text] [Related]
38. Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
Fukasawa T; Yoshizaki A; Ebata S; Nakamura K; Saigusa R; Miura S; Yamashita T; Hirabayashi M; Ichimura Y; Taniguchi T; Asano Y; Shimizu H; Kazoe Y; Mawatari K; Kitamori T; Sato S
Arthritis Rheumatol; 2017 Sep; 69(9):1879-1890. PubMed ID: 28556548
[TBL] [Abstract][Full Text] [Related]
39. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization.
Ma XL; Qu XD; Yang WJ; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Clin Chim Acta; 2020 Dec; 511():67-74. PubMed ID: 32979338
[TBL] [Abstract][Full Text] [Related]
40. Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer.
Sun J; Qiu MZ; Mei T; Gao Y; Chang B; Zhang Y; Wang FH; Li S
Transl Cancer Res; 2020 Apr; 9(4):2434-2448. PubMed ID: 35117603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]